Pharmacy chains activity analysis

Pharmacy chains activity analysis

Russian pharmaceuticals retail chain segment evaluation, both on the level of the state and in particular regions. Pharmacy chains development forecast


Product sales and separate market development forecast, based on unique mathematical models

Business and marketing plan development

Development of detailed business-plans, required to evaluate the reasonability of project start

Search of partners for contract production in Russia

Potential partners search and evaluation, based on their technical opportunities, appropriate experience, and reputation

Monitoring of import substitution

assessment of the main trends of import substitution policies and localization processes in the pharmaceutical market in Russia, the key beneficiaries and companies at risk

Pharmaceutical Drug Production in Russia in 2020 (by Federal Districts)

Wednesday, February 24, 2021

In 2020, the Central Federal District manufactured RUB bln 291.4 worth of ready-made pharmaceuticals (manufacturers’ prices, VAT included), accounting for almost 55% of the total drug production in Russia in monetary terms. However, the growth rate in monetary terms is somewhat lower than the national average – +20%, while the national average exceeded +25.6%.

The production volume in physical terms in the Central Federal District amounted to 2.25 bln units, or 46% of the total volume in Russia. At the same time, the growth rate in physical terms is slightly higher than the national average – +5% against +4.3%. However, that is far from record-worthy, with the North Caucasian Federal District having the growth rate of +9% (the Stavropol-based company Escom contributed to the growth rate the most). The Siberian Federal District has the highest growth rates in physical terms (+24%). The two companies contributed to the growth rates: Novosibirsk-based Obnovlenie and Usolye-Sibirskoye Chemical and Pharmaceutical Plant. The Far Eastern Federal District showed the worst growth rates of -4%. In particular, the production of Dalkhimfarm decreased.

The Southern and North Caucasian Federal Districts have the best growth rates in monetary terms (rubles), with +73% and +64%, respectively. However, the total production volume in the regions in monetary terms accounts to only 2% of the total volume in Russia. Proizvodstvo Medikamentov, based in the Rostov Region (Southern Federal District), is worth mentioning: last year, the enterprise was actively increasing the production of Azithromycin, which was in high demand due to the COVID-19 pandemic.

Despite the negative growth rates in physical terms, the Far Eastern Federal District showed a significant increase in the production volume in monetary terms – +45%, which is the fourth-best result in the overall ranking.

Volumes and growth rates of pharmaceutical drug production in Russia, including production of pharmaceuticals of foreign companies on owned or contract plants, in physical (units) and monetary terms (RUB, VAT included) (2020)